News >

Published Results Confirm Regorafenib Safety, Efficacy in mCRC

Jason Harris
Published: Tuesday, Sep 11, 2018

Dr. Eric Van Cutsem

Eric Van Cutsem, MD, PhD

Safety and efficacy findings for regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (mCRC) were consistent with previous phase III results, according to findings from the phase IIIb CONSIGN trial, now published in The Oncologist.1

“Patients with mCRC who fail treatment with standard therapies, including chemotherapy and monoclonal antibodies targeting VEGF or EGFR, have few treatment options. The multikinase inhibitor regorafenib was shown to improve survival in patients with treatment-refractory mCRC in the phase III CORRECT (N = 760) and CONCUR (N = 204) trials,” lead author Eric van Cutsem, MD, University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, and colleagues wrote.

“However, safety data on regorafenib for mCRC in a larger number of patients were not available. The CONSIGN trial, carried out prospectively in more than 2800 patients across 25 countries, confirmed the safety profile of regorafenib from the phase III trials and reinforced the importance of using treatment modifications to manage adverse events,” continued van Cutsem, et al.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x